@article{bao_clinical_2017-1,
	title = {Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.},
	volume = {36},
	issn = {1435-4373},
	abstract = {The purpose of this study was to assess the pharmacokinetic (PK) characteristics, clinical efficiency, and pharmacoeconomic parameters of piperacillin/tazobactam administered by extended infusion (EI) or intermittent infusion (II) in the treatment of hospital-acquired pneumonia (HAP) in critically ill patients with low illness severity in China. Fifty patients completed the study, with 25 patients receiving 4/0.5 g piperacillin/tazobactam over 30 min as the II group and 25 patients receiving 4/0.5 g piperacillin/tazobactam over 3 h every 6 h as the EI group. Drug assay was performed using high-performance liquid chromatography (HPLC). The percentage of the dosing interval for which the free piperacillin concentration (\%fT) exceeds the minimum inhibitory concentration (MIC) was calculated. The patients' therapy cost, clinical efficiency, and adverse effects were also recorded. \%fT{\textgreater}MIC was about 100, 98.73, and 93.04 \% in the EI arm versus 81.48, 53.29, and 42.15 \% in the II arm, respectively, when the microorganism responsible for HAP had an MIC of 4, 8, and 16 mg/L. The therapy cost in the EI group was lower than that of the II group (\$1351.72+/-120.39 vs. \$1782.04+/-164.51, p=0.001). However, the clinical success rate, clinical failure rate, and drug-related adverse events did not significantly differ between groups. EI treatment with piperacillin/tazobactam was a cost-effective approach to the management of HAP, being equally clinically effective to conventional II.},
	number = {3},
	journal = {European journal of clinical microbiology \& infectious diseases : official publication of the European Society of Clinical Microbiology},
	author = {Bao, H and Lv, Y and Wang, D and Xue, J and Yan, Z},
	year = {2017},
	note = {Bao, H. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Bao, H. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Lv, Y. Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Lv, Y. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Wang, D. Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Wang, D. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Xue, J. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Xue, J. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.
Yan, Z. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. zhao.yan0219@hotmail.com.
Yan, Z. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. zhao.yan0219@hotmail.com.},
	keywords = {*Anti-Bacterial Agents/ad [Administration \& Dosage], *Cross Infection/dt [Drug Therapy], *Penicillanic Acid/aa [Analogs \& Derivatives], *Pneumonia, Bacterial/dt [Drug Therapy], *beta-Lactamase Inhibitors/ad [Administration \& Dosage], Aged, 80 and over, Anti-Bacterial Agents/ec [Economics], Anti-Bacterial Agents/pd [Pharmacology], Anti-Bacterial Agents/pk [Pharmacokinetics], China, Chromatography, High Pressure Liquid, Costs and Cost Analysis, Drug-Related Side Effects and Adverse Reactions, Humans, Infusions, Intravenous/ec [Economics], Infusions, Intravenous/mt [Methods], Microbial Sensitivity Tests, Penicillanic Acid/ad [Administration \& Dosage], Penicillanic Acid/ec [Economics], Penicillanic Acid/pd [Pharmacology], Penicillanic Acid/pk [Pharmacokinetics], Piperacillin/ad [Administration \& Dosage], Piperacillin/ec [Economics], Piperacillin/pd [Pharmacology], Piperacillin/pk [Pharmacokinetics], Plasma/ch [Chemistry], adolescent, adult, aged, beta-Lactamase Inhibitors/ec [Economics], beta-Lactamase Inhibitors/pd [Pharmacology], beta-Lactamase Inhibitors/pk [Pharmacokinetics], critical illness, female, male, middle aged, treatment outcome, young adult},
	pages = {459--466}
}

{"_id":"6wCi6BJWFzFSjf9Yk","bibbaseid":"bao-lv-wang-xue-yan-clinicaloutcomesofextendedversusintermittentadministrationofpiperacillintazobactamforthetreatmentofhospitalacquiredpneumoniaarandomizedcontrolledtrial-2017","downloads":0,"creationDate":"2017-05-12T19:33:31.288Z","title":"Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.","author_short":["Bao, H","Lv, Y","Wang, D","Xue, J","Yan, Z"],"year":2017,"bibtype":"article","biburl":"http://bibbase.org/zotero/gxu917","bibdata":{"bibtype":"article","type":"article","title":"Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.","volume":"36","issn":"1435-4373","abstract":"The purpose of this study was to assess the pharmacokinetic (PK) characteristics, clinical efficiency, and pharmacoeconomic parameters of piperacillin/tazobactam administered by extended infusion (EI) or intermittent infusion (II) in the treatment of hospital-acquired pneumonia (HAP) in critically ill patients with low illness severity in China. Fifty patients completed the study, with 25 patients receiving 4/0.5 g piperacillin/tazobactam over 30 min as the II group and 25 patients receiving 4/0.5 g piperacillin/tazobactam over 3 h every 6 h as the EI group. Drug assay was performed using high-performance liquid chromatography (HPLC). The percentage of the dosing interval for which the free piperacillin concentration (%fT) exceeds the minimum inhibitory concentration (MIC) was calculated. The patients' therapy cost, clinical efficiency, and adverse effects were also recorded. %fT\\textgreaterMIC was about 100, 98.73, and 93.04 % in the EI arm versus 81.48, 53.29, and 42.15 % in the II arm, respectively, when the microorganism responsible for HAP had an MIC of 4, 8, and 16 mg/L. The therapy cost in the EI group was lower than that of the II group (\\$1351.72+/-120.39 vs. \\$1782.04+/-164.51, p=0.001). However, the clinical success rate, clinical failure rate, and drug-related adverse events did not significantly differ between groups. EI treatment with piperacillin/tazobactam was a cost-effective approach to the management of HAP, being equally clinically effective to conventional II.","number":"3","journal":"European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology","author":[{"propositions":[],"lastnames":["Bao"],"firstnames":["H"],"suffixes":[]},{"propositions":[],"lastnames":["Lv"],"firstnames":["Y"],"suffixes":[]},{"propositions":[],"lastnames":["Wang"],"firstnames":["D"],"suffixes":[]},{"propositions":[],"lastnames":["Xue"],"firstnames":["J"],"suffixes":[]},{"propositions":[],"lastnames":["Yan"],"firstnames":["Z"],"suffixes":[]}],"year":"2017","note":"Bao, H. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Bao, H. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Lv, Y. Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Lv, Y. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Wang, D. Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Wang, D. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Xue, J. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Xue, J. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. Yan, Z. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. zhao.yan0219@hotmail.com. Yan, Z. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. zhao.yan0219@hotmail.com.","keywords":"*Anti-Bacterial Agents/ad [Administration & Dosage], *Cross Infection/dt [Drug Therapy], *Penicillanic Acid/aa [Analogs & Derivatives], *Pneumonia, Bacterial/dt [Drug Therapy], *beta-Lactamase Inhibitors/ad [Administration & Dosage], Aged, 80 and over, Anti-Bacterial Agents/ec [Economics], Anti-Bacterial Agents/pd [Pharmacology], Anti-Bacterial Agents/pk [Pharmacokinetics], China, Chromatography, High Pressure Liquid, Costs and Cost Analysis, Drug-Related Side Effects and Adverse Reactions, Humans, Infusions, Intravenous/ec [Economics], Infusions, Intravenous/mt [Methods], Microbial Sensitivity Tests, Penicillanic Acid/ad [Administration & Dosage], Penicillanic Acid/ec [Economics], Penicillanic Acid/pd [Pharmacology], Penicillanic Acid/pk [Pharmacokinetics], Piperacillin/ad [Administration & Dosage], Piperacillin/ec [Economics], Piperacillin/pd [Pharmacology], Piperacillin/pk [Pharmacokinetics], Plasma/ch [Chemistry], adolescent, adult, aged, beta-Lactamase Inhibitors/ec [Economics], beta-Lactamase Inhibitors/pd [Pharmacology], beta-Lactamase Inhibitors/pk [Pharmacokinetics], critical illness, female, male, middle aged, treatment outcome, young adult","pages":"459--466","bibtex":"@article{bao_clinical_2017-1,\n\ttitle = {Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.},\n\tvolume = {36},\n\tissn = {1435-4373},\n\tabstract = {The purpose of this study was to assess the pharmacokinetic (PK) characteristics, clinical efficiency, and pharmacoeconomic parameters of piperacillin/tazobactam administered by extended infusion (EI) or intermittent infusion (II) in the treatment of hospital-acquired pneumonia (HAP) in critically ill patients with low illness severity in China. Fifty patients completed the study, with 25 patients receiving 4/0.5 g piperacillin/tazobactam over 30 min as the II group and 25 patients receiving 4/0.5 g piperacillin/tazobactam over 3 h every 6 h as the EI group. Drug assay was performed using high-performance liquid chromatography (HPLC). The percentage of the dosing interval for which the free piperacillin concentration (\\%fT) exceeds the minimum inhibitory concentration (MIC) was calculated. The patients' therapy cost, clinical efficiency, and adverse effects were also recorded. \\%fT{\\textgreater}MIC was about 100, 98.73, and 93.04 \\% in the EI arm versus 81.48, 53.29, and 42.15 \\% in the II arm, respectively, when the microorganism responsible for HAP had an MIC of 4, 8, and 16 mg/L. The therapy cost in the EI group was lower than that of the II group (\\$1351.72+/-120.39 vs. \\$1782.04+/-164.51, p=0.001). However, the clinical success rate, clinical failure rate, and drug-related adverse events did not significantly differ between groups. EI treatment with piperacillin/tazobactam was a cost-effective approach to the management of HAP, being equally clinically effective to conventional II.},\n\tnumber = {3},\n\tjournal = {European journal of clinical microbiology \\& infectious diseases : official publication of the European Society of Clinical Microbiology},\n\tauthor = {Bao, H and Lv, Y and Wang, D and Xue, J and Yan, Z},\n\tyear = {2017},\n\tnote = {Bao, H. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nBao, H. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nLv, Y. Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nLv, Y. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nWang, D. Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nWang, D. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nXue, J. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nXue, J. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China.\nYan, Z. Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. zhao.yan0219@hotmail.com.\nYan, Z. Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China. zhao.yan0219@hotmail.com.},\n\tkeywords = {*Anti-Bacterial Agents/ad [Administration \\& Dosage], *Cross Infection/dt [Drug Therapy], *Penicillanic Acid/aa [Analogs \\& Derivatives], *Pneumonia, Bacterial/dt [Drug Therapy], *beta-Lactamase Inhibitors/ad [Administration \\& Dosage], Aged, 80 and over, Anti-Bacterial Agents/ec [Economics], Anti-Bacterial Agents/pd [Pharmacology], Anti-Bacterial Agents/pk [Pharmacokinetics], China, Chromatography, High Pressure Liquid, Costs and Cost Analysis, Drug-Related Side Effects and Adverse Reactions, Humans, Infusions, Intravenous/ec [Economics], Infusions, Intravenous/mt [Methods], Microbial Sensitivity Tests, Penicillanic Acid/ad [Administration \\& Dosage], Penicillanic Acid/ec [Economics], Penicillanic Acid/pd [Pharmacology], Penicillanic Acid/pk [Pharmacokinetics], Piperacillin/ad [Administration \\& Dosage], Piperacillin/ec [Economics], Piperacillin/pd [Pharmacology], Piperacillin/pk [Pharmacokinetics], Plasma/ch [Chemistry], adolescent, adult, aged, beta-Lactamase Inhibitors/ec [Economics], beta-Lactamase Inhibitors/pd [Pharmacology], beta-Lactamase Inhibitors/pk [Pharmacokinetics], critical illness, female, male, middle aged, treatment outcome, young adult},\n\tpages = {459--466}\n}\n\n","author_short":["Bao, H","Lv, Y","Wang, D","Xue, J","Yan, Z"],"key":"bao_clinical_2017-1","id":"bao_clinical_2017-1","bibbaseid":"bao-lv-wang-xue-yan-clinicaloutcomesofextendedversusintermittentadministrationofpiperacillintazobactamforthetreatmentofhospitalacquiredpneumoniaarandomizedcontrolledtrial-2017","role":"author","urls":{},"keyword":["*Anti-Bacterial Agents/ad [Administration & Dosage]","*Cross Infection/dt [Drug Therapy]","*Penicillanic Acid/aa [Analogs & Derivatives]","*Pneumonia","Bacterial/dt [Drug Therapy]","*beta-Lactamase Inhibitors/ad [Administration & Dosage]","Aged","80 and over","Anti-Bacterial Agents/ec [Economics]","Anti-Bacterial Agents/pd [Pharmacology]","Anti-Bacterial Agents/pk [Pharmacokinetics]","China","Chromatography","High Pressure Liquid","Costs and Cost Analysis","Drug-Related Side Effects and Adverse Reactions","Humans","Infusions","Intravenous/ec [Economics]","Infusions","Intravenous/mt [Methods]","Microbial Sensitivity Tests","Penicillanic Acid/ad [Administration & Dosage]","Penicillanic Acid/ec [Economics]","Penicillanic Acid/pd [Pharmacology]","Penicillanic Acid/pk [Pharmacokinetics]","Piperacillin/ad [Administration & Dosage]","Piperacillin/ec [Economics]","Piperacillin/pd [Pharmacology]","Piperacillin/pk [Pharmacokinetics]","Plasma/ch [Chemistry]","adolescent","adult","aged","beta-Lactamase Inhibitors/ec [Economics]","beta-Lactamase Inhibitors/pd [Pharmacology]","beta-Lactamase Inhibitors/pk [Pharmacokinetics]","critical illness","female","male","middle aged","treatment outcome","young adult"],"downloads":0,"html":""},"search_terms":["clinical","outcomes","extended","versus","intermittent","administration","piperacillin","tazobactam","treatment","hospital","acquired","pneumonia","randomized","controlled","trial","bao","lv","wang","xue","yan"],"keywords":["*anti-bacterial agents/ad [administration & dosage]","*cross infection/dt [drug therapy]","*penicillanic acid/aa [analogs & derivatives]","*pneumonia","bacterial/dt [drug therapy]","*beta-lactamase inhibitors/ad [administration & dosage]","aged","80 and over","anti-bacterial agents/ec [economics]","anti-bacterial agents/pd [pharmacology]","anti-bacterial agents/pk [pharmacokinetics]","china","chromatography","high pressure liquid","costs and cost analysis","drug-related side effects and adverse reactions","humans","infusions","intravenous/ec [economics]","infusions","intravenous/mt [methods]","microbial sensitivity tests","penicillanic acid/ad [administration & dosage]","penicillanic acid/ec [economics]","penicillanic acid/pd [pharmacology]","penicillanic acid/pk [pharmacokinetics]","piperacillin/ad [administration & dosage]","piperacillin/ec [economics]","piperacillin/pd [pharmacology]","piperacillin/pk [pharmacokinetics]","plasma/ch [chemistry]","adolescent","adult","aged","beta-lactamase inhibitors/ec [economics]","beta-lactamase inhibitors/pd [pharmacology]","beta-lactamase inhibitors/pk [pharmacokinetics]","critical illness","female","male","middle aged","treatment outcome","young adult"],"authorIDs":[],"dataSources":["9LqPNaySNpNxYBFzj"]}